|
|
|
Volumn 41, Issue 2, 2011, Pages 511-557
|
|
Implementation of the biosimilar pathway: economic and policy issues.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOLOGICAL PRODUCT;
GENERIC DRUG;
ARTICLE;
COST CONTROL;
DRUG APPROVAL;
DRUG LEGISLATION;
ECONOMIC ASPECT;
ECONOMICS;
EUROPEAN UNION;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE POLICY;
HUMAN;
LEGAL ASPECT;
MASS COMMUNICATION;
MEDICAID;
MEDICARE;
PATENT;
PHARMACOKINETICS;
REIMBURSEMENT;
STANDARD;
UNITED STATES;
BIOLOGICAL PRODUCTS;
COST SAVINGS;
DIFFUSION OF INNOVATION;
DRUG APPROVAL;
DRUGS, GENERIC;
ECONOMIC COMPETITION;
EUROPEAN UNION;
HEALTH CARE REFORM;
HEALTH POLICY;
HUMANS;
LEGISLATION, DRUG;
MEDICAID;
MEDICARE;
PATENTS AS TOPIC;
REIMBURSEMENT MECHANISMS;
THERAPEUTIC EQUIVALENCY;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 79960574826
PISSN: 05865964
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (20)
|
|
References (0)
|
